NextPlat (NXPL) Income from Non-Controlling Interests (2016 - 2026)
NextPlat's (NXPL) quarterly Income from Non-Controlling Interests came in at -$14000.0 in Q1 2026, down 117.72% quarter-over-quarter from $79000.0 in Q4 2025.
Powered by 
Analysis
NextPlat (NXPL) Income from Non-Controlling Interests (2016 - 2026) Analysis & Trends
NextPlat (NXPL) has reported Income from Non-Controlling Interests for 8 consecutive years, with -$14000.0 the latest figure, recorded in Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests changed N/A year-over-year to -$14000.0 in Q1 2026; TTM through Jun 2026 was $65000.0, a 101.89% increase from a year earlier, with the FY2025 full-year figure at $79000.0, up 100.87% from the prior year.
- Income from Non-Controlling Interests was -$14000.0 for Q1 2026 at NextPlat, down from $79000.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $106000.0 in Q4 2022 and troughed at -$7.8 million in Q4 2023.
- A 5-year average of -$2.2 million and a median of -$515500.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests tumbled 7475.47% in 2023 and slumped 325.15% in 2024, its largest moves.
- Over 5 years, Income from Non-Controlling Interests stood at $106000.0 in 2022, then plunged by 7475.47% to -$7.8 million in 2023, then soared by 55.9% to -$3.4 million in 2024, then soared by 102.29% to $79000.0 in 2025, then tumbled by 117.72% to -$14000.0 in 2026.
- The last three Income from Non-Controlling Interests figures came in at -$14000.0 (Q1 2026), $79000.0 (Q4 2025), and -$3.4 million (Q3 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | - |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | - |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | -918,959.97 |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 11.95 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 2.00 Mn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | - |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | - |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | - |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | - |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -14,000.00 |
| Dec 31, 2025 | 79,000.00 |
| Sep 30, 2024 | -3.45 Mn |
| Jun 30, 2024 | -5.43 Mn |
| Mar 31, 2024 | -220,000.00 |
| Dec 31, 2023 | -7.82 Mn |
| Sep 30, 2023 | -811,000.00 |
| Dec 31, 2022 | 106,000.00 |
| Dec 31, 2018 | -651,405.00 |
| Sep 30, 2018 | 337,938.00 |
| Jun 30, 2018 | 135,747.00 |
| Mar 31, 2018 | -140,458.00 |
| Dec 31, 2017 | -2.74 Mn |
| Sep 30, 2017 | 247,214.00 |
| Jun 30, 2017 | 3.12 Mn |
| Mar 31, 2017 | -213,670.00 |
| Sep 30, 2016 | -318,874.00 |
| Jun 30, 2016 | -1.17 Mn |
| Mar 31, 2016 | 61,985.00 |